Global Blood Group Typing Market Overview
Blood Group Typing Market Size was valued at USD 2.1 Billion in 2022. The Blood Group Typing Market industry is projected to grow from USD 2.29 Billion in 2023 to USD 4.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.90% during the forecast period (2023 - 2032).The increasing percentage of accidents and growth in people donating blood are market drivers expediting the market’s expansion.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Additionally, in June 2023, Quotient Limited (Switzerland) introduced its ALBA products into the Netherlands and Sweden as well as Austria, France, Germany, Greece, Hungary, Italy, Luxembourg, The Netherlands, Poland Romania Slovakia and Sweden.
Moreover this IH-500TM Next System was launched by Bio-Rad Laboratories Inc. of the United States throughout May 2023 which is fully automated system for ID cards. The IH-500 NEXT System does not only reduce instrument downtime and improve laboratory efficiency but also allows one to use high-performance Bio-Rad Reagent RBCs or the lab’s own RBCs/Third Party Reagent RBCs as well.
In addition to that Transmedic Pte Ltd (Singapore) got into a distribution agreement with Quotient Limited (Switzerland) in June 2023. This will enable Transmedic to distribute Alba by Quotient and MosaiQ in five countries in Southeast Asia.
Moreover, Werfen Spain acquired Immucor Inc., which increased its presence as a reference company in the specialized diagnostics market and developed its portfolio of diagnostic solutions for hospitals and clinical laboratories.
Similarly, Werfen has completed the acquisition of Immucor Inc., having received all required regulatory and antitrust approvals. Immucor is a private US-based firm involved in the in-vitro diagnostics (IVD) sector with a significant global presence in the transfusion and transplantation markets.
Additionally Grifols expanded its plasma-derived pharmaceutical business through acquiring 100% shares of Tiancheng (Germany) Pharmaceutical Holdings AG. Therefore, this acquisition enables Grifols to expand patient access to plasma medicines further, quicken and broaden product range, operate the most extensive private European network of plasma facilities (87 sites), increase business and margin expansion following recent acquisitions such as Biotest AG majority owned by Tiancheng(Germany)Pharmaceutical Holdings AG.
Grifols partnered with Endpoint Health, Inc. in February 2022 to expand their product portfolio for blood group typing.
Market CAGR for blood group typing is being driven by the rise in the number of road accidents. The market’s growth is significantly influenced by the rising incidence of breast cancer. A growing number of blood transfusions due to an increase in traffic accidents, rising blood transfusion rates, and expanding demand for blood and related goods are some of the reasons anticipated to support growth. Prior to blood transfusions, blood group typing is a required test that determines the Rh factor as well as the degree of blood compatibility between the donor and the recipient. The market is expected to continue to expand as a result of increasing utilization of these tests for the identification of Hemolytic Disease of the Newborn (HDN).
Major biotechnology and healthcare companies involved in this sector concentrate on creating cutting-edge tools and products for identifying blood group types at the molecular level. For instance, the blood banks use the adaptable DNA microarray platform that enables the processing of genotypes and blood samples for thorough screening at affordable pricing.
Additionally, businesses are putting more and more effort into creating technologies that can effectively manage the workload associated with blood tests. For example, the Food and Drug Administration (FDA) approved Immucor's PreciseType HEA test in November 2016 for use in the identification of sickle cell characteristics in blood donors. National rules for ensuring everyone has access to safe blood are being developed and implemented by several regulatory organizations, including the FDA. Thus, driving the Blood Group Typing Market revenue.
The Blood Group Typing Market segmentation, based on test type includes Antibody screening, HLA typing, ABO blood tests, Cross-matching tests, and Antigen typing. As the demand for early diagnosis and the increasing frequency of chronic diseases is rising, the antibody screening market category retained the greatest market share. In addition, one of the key factors fueling the segment's expansion is the rising spread of transfusion-transmitted infections (TTIs), particularly in lower-middle-income and low-income countries.
The Blood Group Typing Market segmentation, based on technique, includes PCR-based and microarray techniques, array-based techniques, and massively parallel sequencing. Due to growing R&D efforts on antibody-antigen interactions and the high frequency of chronic disorders such as sickle cell anemia, traumatic injuries, and leukemia, the PCR-based and microarray techniques segment held the biggest share.
The Blood Group Typing Market segmentation, based on products and services, includes Consumables, Antisera reagents, Red blood cell reagents, Anti-human globulin reagents, Blood bank saline, Instruments, and Services. Due to the rise in surgical operations such as organ transplants and the use of serological fluids and reagents in laboratories, the consumables segment maintained the greatest market share. The elevated blood donation rates that result in more blood sample analysis are another factor contributing to the expansion.
The Blood Group Typing Market segmentation, based on end-user, includes Hospitals, Blood banks, Clinical Laboratories, and Others. The largest share belonged to the blood banks segment. Blood banks perform a crucial function by keeping blood on hand for use in the future. The significance of blood group typing is projected to increase as the trend of blood donation out of social concern increases.
Figure 1: Blood Group Typing Market, by End-User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Blood Group Typing Market area will dominate this market. This is due to an increase in transfusions in high-income nations like the United States. Data from the World Health Organization (WHO) show that 42% of blood donations in 2019 came from high-income nations.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: BLOOD GROUP TYPING MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe’s Blood Group Typing Market accounts for the second-largest position in the market. The market is expanding at an accelerated rate due to the growing adoption of technically advanced tests and methods of blood typing. Further, the UK Blood Group Typing Market held the largest market share, and the Germany Blood Group Typing Market was the quickest-growing market in the European region
The Asia Pacific Blood Group Typing Market is anticipated to expand at the quickest CAGR. Growing concern over the prevalence of infectious diseases in this area is what's fueling industrial expansion. Moreover, China Blood Group Typing Market held the fastest CAGR, and the India Blood Group Typing Market was the quickest-growing market in the Asia-Pacific region.
Blood Group Typing Key Market Players & Competitive Insights
Leading market players are investing largely in research & development-related activities to extend their product/service lines, which will aid the Blood Group Typing Market, to grow faster. Market leaders are also adopting a range of strategies to expand their worldwide position, with important market developments including new product launches & developments, contractual agreements among companies with complementary service lines, mergers & acquisitions, increased investments, & collaboration with other organizations having complementary products and services. To grow in a competitive and rising market climate, the Blood Group Typing industry needs to offer cost-efficient products.
Producing locally to cut operational expenses is one of the prime business strategies used by manufacturers in the Blood Group Typing industry to benefit clients and increase the market sector. In recent years, the Blood Group Typing industry has served with some of the key perks of medicine. Major players in the Blood Group Typing Market, including Bio-Rad Laboratories Inc., Grifols International, Beckman Coulter, Immucor Inc., Ortho Clinical Diagnostics Inc., Quotient Ltd., Novacyt Group, Bag Healthcare GmbH, Rapid Labs, AXO Science, Agena Biosciences Inc., Day Medical SA, Merck KGaA, and others are attempting to increase market growth via investing in research and development operations.
A digital marketing platform is run by Quotient Technology Inc (Quotient). The business provides media solutions as well as digital coupons, including printable digital coupons, discount codes, digital paperless coupons, and promotions for loyalty cards. Shopper media offerings, national media offerings, DOOH offerings, and sponsored search offerings are some of its digital media services. Consumer packaged goods (CPG) brands, consumers, and retailers are all served by Quotient's range of goods and services. It offers a digital platform for businesses to interact with their customers across their websites, mobile applications, and social media platforms. The business operates in Israel, France, India, Belgium, the United States, and the United Kingdom. Salt Lake City, Utah, in the US, is home to the Quotient headquarters. In March 2022, MosaiQ Extended Immunohematology (IH) Microarray has been awarded the Conformité Européenne (CE) Mark, according to Quotient Limited. The Extended IH Microarray has received the CE certification, indicating that it complies with the European Medical Devices Directive.
A pharmaceutical and chemical manufacturing firm, Grifols SA (Grifols) is committed to enhancing the health & well-being of patients all over the world. Research, development, production, and commercialization of plasma-derived medicines, hospital pharmacy products, and clinically applicable diagnostic technology are its main areas of concentration. The business creates plasma-derived protein treatments for people with rare, persistent, and fatal infections. For use in biotechnology research, producing pharmaceutical and diagnostic goods, and clinical trials, Grifols provides biological materials. Grifols supplies transfusion medicine, hemostasis, & immunoassay solutions for blood banks, clinical laboratories and transfusion centers. Healthcare professionals, pharmacies, and hospitals can purchase the company's products. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain. In March 2021, Grifols revealed that the DG Reader Net semi-automated analyzer, which is used to facilitate pre-transfusion blood type compatibility testing, had been installed for the first time in North America. ThedaCare Medical Center-Wild Rose in Wisconsin is currently using this platform, the most recent addition to the business' scalable solutions for blood banks.
Key Companies in the Blood Group Typing Market include
Grifols International
Immucor Inc.
Ortho Clinical Diagnostics Inc.
Quotient Ltd.
Novacyt Group
Bag Healthcare GmbH
Rapid Labs
AXO Science
Agena Biosciences Inc.
Day Medical SA
Merck KGaA
Blood Group Typing Industry Developments
April 2022:Tiancheng (Germany) Pharmaceutical Holdings AG's 100% share capital has been acquired by Grifols. By purchasing Biotest AG, which is primarily owned by Tiancheng (Germany) Pharmaceutical Holdings AG, Gricanle to expand and speed up the development of its product line, increase patient access to plasma medicines, run the largest private European network of plasma facilities (87 sites), boost revenue growth, and increase profit margins.
June 2021:A partnership between Bio-Rad Laboratories and Seegene was launched to produce and market molecular diagnostic tools for infectious diseases.
Antibody screening
HLA typing
ABO blood tests
Cross-matching tests
Antigen typing
PCR-based and microarray technique
Array-based technique
Massively parallel sequencing
Consumables
Antisera reagents
Red blood cell reagents
Anti-human globulin reagents
Blood bank saline
Instruments
Services
Hospitals
Blood banks
Clinical Laboratories
Others
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)